Overview
Signios Bio provides an integrated suite of multiomic technologies including genomics, transcriptomics, proteomics, epigenomics, metabolomics, microbiomics, and spatial biology, powered by a proprietary AI-driven bioinformatics platform. The company offers next-generation sequencing services such as whole-genome sequencing, whole-exome sequencing, single-cell RNA-seq, spatial transcriptomics, and long-read PacBio sequencing. These capabilities support pharmaceutical companies, biotech firms, and academic institutions in decoding disease biology, identifying biomarkers, and advancing precision medicine and drug discovery.
Frequently asked questions
- What multiomics and sequencing services does Signios Bio offer?
- Signios Bio offers whole-genome sequencing, whole-exome sequencing, bulk and single-cell RNA-seq, spatial transcriptomics, targeted NGS panels, ATAC-Seq, ChIP-Seq, bisulfite sequencing, TCR/BCR profiling, and long-read PacBio HiFi sequencing, alongside proteomics, epigenomics, metabolomics, and microbiomics powered by AI bioinformatics.
- What platforms does Signios Bio use for single-cell sequencing?
- Signios Bio is a 10x Genomics-certified provider using Chromium platforms for single-cell RNA-seq, immune profiling, single-nuclei sequencing, and ATAC-seq, plus BD Rhapsody platforms, with automated sample prep and AI analysis.
- How does Signios Bio support drug discovery and precision medicine?
- Signios Bio's AI-driven platform integrates multiomic data to decode complex disease biology, identify novel biomarkers, and accelerate discovery of targeted therapies and diagnostics for pharma, biotech, and academic researchers.